Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

10/06/2016 | 12:02pm EST

NEW YORK, Oct. 6, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY) (ISIN: US02043Q1076). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Alnylam and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

[Click here to join a class action]

On October 5, 2016, Alnylam announced that the Company had decided to discontinue development of revusiran, an investigational RNA interference therapeutic that Alnylam was developing for the treatment of hereditary ATTR amyloidosis with cardiomyopathy, citing patient safety concerns. The Company stated that its decision was prompted by reports that patients taking the revusiran drug in midstage trials had new or worsening complications of the disease.

On this news, Alnylam stock has fallen as much as $34.68, or 49.33%, to $35.62 during intraday trading on October 6, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-alnylam-pharmaceuticals-inc--alny-300340678.html

SOURCE Pomerantz LLP


© PRNewswire 2016
All news about ALNYLAM PHARMACEUTICALS, INC.
01/13ALNYLAM PHARMACEUTICALS : Cowen Adjusts Price Target on Alnylam Pharmaceuticals ..
MT
01/11ALNYLAM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
AQ
01/10ALNYLAM PHARMACEUTICALS : Launches “ P5x25” Strategy for Planned Tra..
BU
01/07ALNYLAM PHARMACEUTICALS : Says Late-Stage Study of Vutrisiran Meets Primary Endp..
MT
01/07ALNYLAM PHARMACEUTICALS : Reports Positive Topline Results from HELIOS-A Phase 3..
BU
01/04ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 39th Annual J.P. Morgan Hea..
BU
2020ALNYLAM PHARMACEUTICALS : UBS Adjusts Price Target on Alnylam Pharmaceuticals to..
MT
2020ALNYLAM PHARMACEUTICALS : Appoints Tolga Tanguler Chief Commercial Officer and A..
BU
2020ALNYLAM PHARMACEUTICALS : RBC Adjusts Alnylam Pharmaceuticals' Price Target to $..
MT
2020PRESS RELEASE : Novartis receives complete response letter from U.S. FDA for inc..
DJ
More news